Cyclo Therapeutics, Inc.
CYTH · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $234 | $123 | $202 | $311 |
| % Growth | 89.9% | -39.2% | -35% | – |
| Cost of Goods Sold | $17 | $931 | $836 | $877 |
| Gross Profit | $217 | -$808 | -$634 | -$565 |
| % Margin | 92.8% | -656.4% | -313.2% | -181.5% |
| R&D Expenses | $5,493 | $3,492 | $2,845 | $4,144 |
| G&A Expenses | $2,164 | $1,414 | $1,557 | $1,398 |
| SG&A Expenses | $2,367 | $1,415 | $1,558 | $1,399 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $1 |
| Other Operating Expenses | $646 | -$79 | $540 | -$2,310 |
| Operating Expenses | $8,503 | $4,828 | $4,475 | $5,077 |
| Operating Income | -$8,289 | -$5,636 | -$5,109 | -$5,643 |
| % Margin | -3,546% | -4,578% | -2,523.7% | -1,812% |
| Other Income/Exp. Net | -$544 | -$346 | $766 | $0 |
| Pre-Tax Income | -$8,833 | -$5,981 | -$4,343 | -$5,642 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,833 | -$5,981 | -$4,343 | -$5,642 |
| % Margin | -3,778.4% | -4,858.7% | -2,145.3% | -1,812% |
| EPS | -0.31 | -0.21 | -0.15 | -0.23 |
| % Growth | -47.6% | -40% | 34.8% | – |
| EPS Diluted | -0.31 | -0.21 | -0.15 | -0.23 |
| Weighted Avg Shares Out | 28,730 | 28,639 | 28,585 | 24,869 |
| Weighted Avg Shares Out Dil | 28,730 | 28,639 | 28,585 | 24,869 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $5 |
| EBITDA | -$8,287 | -$5,634 | -$5,107 | -$5,638 |
| % Margin | -3,545% | -4,576.2% | -2,522.6% | -1,810.4% |